153 related articles for article (PubMed ID: 33970738)
1. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
[TBL] [Abstract][Full Text] [Related]
2. Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.
Matos E; Cankar K; Režun N; Dejanović K; Ovčariček T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791907
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP; Okera M; Wildiers H; Campone M; Grischke EM; Manso L; André VAM; Chouaki N; San Antonio B; Toi M; Sledge GW
Breast Cancer Res Treat; 2021 Apr; 186(2):417-428. PubMed ID: 33392835
[TBL] [Abstract][Full Text] [Related]
5. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
[TBL] [Abstract][Full Text] [Related]
6. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
[No Abstract] [Full Text] [Related]
9. Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.
Shimoi T; Pathadka S; Sekine N; Cai Z; Tanizawa Y; Kawaguchi T; Saji S; Yamashita T
Future Oncol; 2024 May; ():1-10. PubMed ID: 38861285
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
Johnston S; O'Shaughnessy J; Martin M; Huober J; Toi M; Sohn J; André VAM; Martin HR; Hardebeck MC; Goetz MP
NPJ Breast Cancer; 2021 Jun; 7(1):80. PubMed ID: 34158513
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2- advanced breast cancer in South Korea, focusing on underrepresented patients.
Jung HI; Kwon SH; Nam JH; Cho JY; Lee EK
Curr Med Res Opin; 2024 May; ():1-9. PubMed ID: 38715458
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review.
Martorana F; Sanò MV; Valerio MR; Fogli S; Vigneri P; Danesi R; Gebbia V
Ther Adv Drug Saf; 2024; 15():20420986231224214. PubMed ID: 38665218
[TBL] [Abstract][Full Text] [Related]
13. Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer.
De Sanctis R; Tiberio P; Jacobs F; Gaudio M; Benvenuti C; Giordano L; Torrisi R; Zambelli A; Pozzi C; Penna G; Santoro A; Rescigno M
Oncologist; 2024 May; ():. PubMed ID: 38767987
[TBL] [Abstract][Full Text] [Related]
14. Can a combination of probiotics and nutraceuticals help preventing the abemaciclib-related diarrhea in breast cancer patients?
Pacetti U; DI Pierro F; Cazzaniga M; Cavecchia I; Matera M; Bertuccioli A; Zerbinati N; Guasti L; Stani SC
Minerva Gastroenterol (Torino); 2024 Jun; 70(2):242-244. PubMed ID: 38483445
[No Abstract] [Full Text] [Related]
15. Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Sherry AD; Lin TA; McCaw ZR; Ludmir EB
Ann Oncol; 2024 Jun; ():. PubMed ID: 38838846
[No Abstract] [Full Text] [Related]
16. To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Orlandi A; Mastrantoni L; Bria E; Tortora G
Ann Oncol; 2024 Jun; ():. PubMed ID: 38838845
[No Abstract] [Full Text] [Related]
17. [A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Kudo S; Makino T; Umetsu R; Tanaka T
Gan To Kagaku Ryoho; 2021 Apr; 48(4):519-521. PubMed ID: 33976037
[TBL] [Abstract][Full Text] [Related]
18. Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
Li C; Li X
Onco Targets Ther; 2021; 14():2929-2939. PubMed ID: 33976551
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Ishiguro A; Tanimoto A; Ito K; Ohigashi A; Kato H; Abe M; Kubota R; Chiba R; Matsunami O; Narita Y
Gan To Kagaku Ryoho; 2021 May; 48(5):697-699. PubMed ID: 34006717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
